COMPANY: ABOUT AMBULERO

Ambulero’s first-in-class gene and cell therapy programs are based on over a decade of ground-breaking work from the laboratories of Dr. Omaida Velazquez, Professor of Surgery, the University of Miami Miller School of Medicine, and Dr. Zhao-Jun Liu, Professor of Surgery, University of Miami Miller School of Medicine. Dr. Velazquez  and Dr. Liu are  principal investigators of NIH-funded research that is seeking to  understand vascular biology better by seeing how  new blood vessels grow in response to disease. This work was  selected for prestigious funding under NIH’s Vascular Interventions/Innovations and Therapeutic Advances (VITA) program, the Catalyze program of the NHLBI and the Wallace Coulter Center For Translational Research at the University of Miami (see “Investors and Development” for more information).

​

For more background information on the basic research behind our first-in-class cell and gene therapy approaches, please refer to scientific publications from the laboratories of Dr. Omaida Velazquez and Dr. Zhao-Jun Liu.

​

Ambulero is a spin-out of the University of Miami Miller School of Medicine fighting vascular disease and non-healing wounds with innovation.

​